Is platinib a targeted therapy drug?

Pralsetinib is a targeted therapy drug designed to treat certain types of cancer, especially those with specific genetic mutations. It belongs to a class of drugs called tyrosine kinase inhibitors (TKI), which interfere with the growth and spread of tumor cells by targeting specific receptors, thus exerting a therapeutic effect. Platinib targets mutations in the RET gene. RET gene mutation is one of the pathological foundations of various cancers, especially common innon-small cell lung cancer (NSCLC)and thyroid cancer. RET gene mutations can lead to abnormal growth and proliferation of tumor cells. Therefore, Platinib effectively controls the growth of cancer cells by inhibiting the tyrosine kinase activity of this mutation.

Platinib was approved by the U.S. Food and Drug Administration (FDA) to treat patients with non-small cell lung cancer (NSCLC) with RET gene mutations or fusions, especially when these patients' tumors are insensitive to traditional treatments. Platinib provides them with a new treatment option. In addition to non-small cell lung cancer, platinib has also been used in the treatment of thyroid cancer and other diseases related to RET mutations, showing certain efficacy. The drug inhibits tumor growth and metastasis by precisely targeting mutations in the RET gene, and is therefore widely regarded as a targeted therapy.

One of the characteristics of targeted therapy drugs is the precision of their treatment, and it is by virtue of this advantage that Platinib has emerged in cancer treatment. Unlike traditional chemotherapy drugs, targeted drugs do not rely on killing all rapidly dividing cells, but target specific molecules or genetic mutations present in cancer cells, thereby reducing damage to normal cells and reducing the occurrence of side effects. Therefore, platinib, as a targeted therapy, has high therapeutic selectivity and good tolerance.

Reference: https://gavreto.com/